CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab
We compared morphologic computed tomography (CT)-based to metabolic fluoro-deoxy-glucose (FDG) positron emission tomography (PET)/CT-based response evaluation in patients with metastatic colorectal cancer and correlated the findings with survival and KRAS status. From 2006 to 2009, patients were inc...
Main Authors: | Skougaard, Kristin, Johannesen, Helle Hjorth, Nielsen, Dorte, Schou, Jakob Vasehus, Jensen, Benny Vittrup, Høgdall, Estrid V S, Hendel, Helle Westergren |
---|---|
Format: | Online |
Language: | English |
Published: |
Blackwell Publishing Ltd
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302679/ |
Similar Items
-
Dual time point imaging fluorine-18 flourodeoxyglucose positron emission tomography for evaluation of large loco-regional recurrences of breast cancer treated with electrochemotherapy
by: Matthiessen, Louise Wichmann, et al.
Published: (2013) -
miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3rd Line Cetuximab and Irinotecan
by: Schou, Jakob V., et al.
Published: (2014) -
FDG-PET/CT in lymphoma
by: D'souza, Maria M, et al.
Published: (2013) -
A prospective trial comparing FDG-PET/CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck
by: Adkins, Douglas, et al.
Published: (2014) -
Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing
by: Christina Demuth, et al.
Published: (2018-10-01)